SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.

Employees

7,689

Sector

Pharmaceuticals

Calendar

04-23 - Q1 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-07	16.87 ¥	-0.53%	4,161,266
25-12-05	16.96 ¥	+0.30%	4,364,871
25-12-04	16.91 ¥	-0.41%	3,137,410
25-12-03	16.98 ¥	+0.12%	3,519,229
25-12-02	16.96 ¥	-1.17%	3,902,543

End-of-day quote Shanghai S.E., December 07, 2025

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2025-12-08			5-day change	1st Jan Change
16.87 ^CNY	-0.53%		-0.59%	+6.77%

12-02	Buchang Pharma Modifies Shaanxi Drug Manufacturing License	MT
11-27	Buchang Pharma Signs Contract for Clinical Trial of Traditional Chinese Drug	MT

Capitalization	17.79B 2.52B 2.17B 2.03B 1.89B 3.48B 227B 3.8B 23.69B 9.18B 107B 9.44B 9.24B 392B	P/E ratio 2023	59x	P/E ratio 2024	-30.9x
Enterprise value	20.28B 2.87B 2.47B 2.32B 2.16B 3.97B 259B 4.33B 27.02B 10.46B 122B 10.77B 10.54B 447B	EV / Sales 2023	1.59x	EV / Sales 2024	1.76x
Free-Float	41.28%	Yield 2023	0.74%	Yield 2024	-

12-02	Buchang Pharma Modifies Shaanxi Drug Manufacturing License	MT
11-27	Buchang Pharma Signs Contract for Clinical Trial of Traditional Chinese Drug	MT
11-27	Buchang Pharma Gets Regulatory Approval for Drug Manufacturing License Changes	MT
11-27	Buchang Pharma Provides 80 Million Yuan Guarantee for Subsidiary Loan	MT
11-26	Buchang Pharma Transfers Key Drug Clinical Development to Subsidiary	MT
11-18	Shandong Buchang Pharmaceuticals Unit to Invest in Biotech JV	MT
10-29	Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
10-28	Jinan Buchang Shengyuan Medical Equipment Co., Ltd. announced that it expects to receive CNY 3 million in funding from Shandong Buchang Pharmaceuticals Co., Ltd.	CI
10-17	Shandong Buchang Pharmaceuticals Unit Signs 11-Million-Yuan Technical Service Contract	MT
10-14	Buchang Pharmaceuticals Gets Nod for Registration of Ibuprofen Capsules	MT
09-30	Regulator OK's Revision in Shandong Buchang Pharmaceuticals' Drug Production License	MT
09-23	Buchang Pharma Gets Approval for Contract Manufacturing for Two Drugs; Shares Down 3%	MT
09-09	Shandong Buchang Pharmaceuticals Gets Contract Manufacturing License	MT

1 day	-0.53%
1 week	-0.59%
Current month	-0.59%
1 month	-2.88%
3 months	-11.77%
6 months	+2.24%
Current year	+6.77%

Shandong Buchang Pharmaceuticals Co., Ltd. Stock

Equities

603858

CNE100002FV6

Pharmaceuticals

Valuation: Shandong Buchang Pharmaceuticals Co., Ltd.

Chart: Shandong Buchang Pharmaceuticals Co., Ltd.

Latest news: Shandong Buchang Pharmaceuticals Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shandong Buchang Pharmaceuticals Co., Ltd.

ETFs: Shandong Buchang Pharmaceuticals Co., Ltd.

Alternative Medicine

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	16.76	17.27
1 month	16.68	18.47
Current year	13.83	20.58
1 year	13.83	20.58
3 years	13.83	27.91
5 years	13.83	28.38
10 years	13.83	91.96

Manager	Title	Age	Since
Bao Cai Wang DFI	Director of Finance/CFO	62	2012-03-10
Chao Zhao PSD	President	58	2012-03-10
Xi Fang Wang CTO	Chief Tech/Sci/R&D Officer	66	2017-03-25

Director	Title	Age	Since
Tao Zhao CHM	Chairman	59	2012-03-10
Chao Zhao BRD	Director/Board Member	58	2012-03-10
Yi Min Wang BRD	Director/Board Member	64	2017-03-25

	2023	2024
Net sales	13.25B 1.87B 1.61B 1.51B 1.41B 2.59B 169B 2.83B 17.64B 6.83B 79.74B 7.03B 6.88B 292B	11.01B 1.56B 1.34B 1.26B 1.17B 2.16B 140B 2.35B 14.66B 5.68B 66.26B 5.84B 5.72B 243B
Net income	319M 45.12M 38.84M 36.46M 33.89M 62.47M 4.07B 68.15M 425M 165M 1.92B 169M 166M 7.04B	-554M -78.33M -67.43M -63.3M -58.84M -108M -7.06B -118M -738M -286M -3.33B -294M -288M -12.21B
Net Debt	2.25B 318M 274M 257M 239M 440M 28.65B 480M 2.99B 1.16B 13.52B 1.19B 1.17B 49.55B	2.49B 353M 304M 285M 265M 488M 31.79B 533M 3.32B 1.29B 15.01B 1.32B 1.3B 54.99B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-0.53%	-0.59%	-1.35%	-31.84%	2.53B
BEIJING TONGRENTANG CO., LTD	-0.60%	-0.69%	-18.20%	-31.52%	6.48B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.38%	+0.81%	+43.15%	+54.85%	4.39B
DONG-E-E-JIAO CO.,LTD.	-0.37%	+1.27%	-16.76%	+22.87%	4.37B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-1.32%	-3.86%	+5.46%	-63.46%	4.3B
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	-0.40%	+3.66%	-7.85%	-12.90%	3.56B
TASLY PHARMACEUTICAL GROUP CO., LTD	-0.52%	-0.39%	+4.95%	+28.32%	3.24B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.20%	-0.04%	+9.63%	+0.04%	1.99B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	-0.36%	+0.60%	-1.26%	+59.09%	1.76B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+1.12%	+0.88%	+2.19%	+51.54%	1.67B
Average	-0.46%	-0.70%	+2.00%	+7.70%	3.43B
Weighted average by Cap.	-0.61%	-0.84%	+0.80%	+0.56%